|
Parkinson Disease
|
0.310 |
Biomarker
|
disease |
CTD_human |
We identified 13 common genes (ADARB2, CEACAM6, CNTNAP2, COL19A1, DEF4, DRAXIN, FCER2, HBG1, NCAPG2, PVRL2, SLC2A14, SNCA, and TCL1B) showing significant differential expression between G2019S-associated PD and asymptomatic carriers and also between idiopathic PD and controls but not between untreated and treated patients.
|
25475535 |
2015 |
|
Encephalitis
|
0.310 |
Biomarker
|
disease |
CTD_human |
In addition, CD23 antigen was co-localized with iNOS and nitrotyrosine on brain tissue from patients with HIV1-related encephalitis, suggesting that CD23 participates in iNOS activation of astrocytes in vivo.
|
11500085 |
2001 |
|
Encephalitis
|
0.310 |
Biomarker
|
disease |
BEFREE |
Role of CD23 in astrocytes inflammatory reaction during HIV-1 related encephalitis.
|
11500085 |
2001 |
|
HIV Infections
|
0.310 |
Biomarker
|
group |
CTD_human |
Role of CD23 in astrocytes inflammatory reaction during HIV-1 related encephalitis.
|
11500085 |
2001 |
|
Parkinson Disease
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells.
|
10212304 |
1999 |
|
HIV Infections
|
0.310 |
GeneticVariation
|
group |
BEFREE |
HIV disease in children is associated with a selective decrease in CD23+ and CD62L+ B cells.
|
8906751 |
1996 |
|
Immediate hypersensitivity
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
How aluminum adjuvants could promote and enhance non-target IgE synthesis in a genetically-vulnerable sub-population.
|
22967010 |
2013 |
|
Rasmussen Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Role of CD23 in astrocytes inflammatory reaction during HIV-1 related encephalitis.
|
11500085 |
2001 |
|
HIV Coinfection
|
0.300 |
Biomarker
|
disease |
CTD_human |
Role of CD23 in astrocytes inflammatory reaction during HIV-1 related encephalitis.
|
11500085 |
2001 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic lymphocytic leukemia (CLL) is characterized by the progressive expansion of B lymphocytes CD5+/CD23+ in peripheral blood, lymph-nodes, and bone marrow.
|
30642077 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
B-cell chronic lymphocytic leukemia (CLL), a low-grade malignancy consisting of CD5(+), CD23(+), and CD43(+) small B lymphocytes, is the most frequent leukemia in the western world.
|
31268930 |
2019 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SOX11-negative MCLs more often showed classic morphology (83% vs. 65%, P=0.005), were more often positive for CD23 (39% vs. 22%, P=0.02) and CD200 (60% vs. 9%, P=0.0001), and had a lower proliferation index (Ki67 23% vs. 33%, P=0.04).
|
30768440 |
2019 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD23+ MCL was also more often positive for CD200 (17% versus.
|
31054894 |
2019 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
On B-cells, ADAM10 cleavage of the low-affinity IgE receptor CD23 promotes allergy and asthma, cleavage of ICOS ligand impairs antibody responses, and cleavage of the BAFF-APRIL receptor transmembrane activator and CAML interactor, and BAFF receptor, reduce B-cell survival.
|
30013551 |
2018 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine whether CD23 plays a role in the inflammatory process in severe uncontrolled asthma and whether anti-IgE therapy modulates fc epsilon RII/CD23 expression in these patients.
|
29279058 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Other cases may coexpress CD19, CD5, bright CD20, and lack CD23 ("atypical CLL"), while others are CD5-negative ("non-CLL").
|
30268574 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD200 was of better diagnostic performance (accuracy: 94.6%) in differentiating CLL from MCL compared with CD23 (accuracy: 93.3%).
|
28752619 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic lymphocytic leukemia (CLL) is characterized by the clonal expansion of small mature-looking CD19+ CD23+ CD5+ B-cells that accumulate in the blood, bone marrow, and lymphoid organs.
|
29670635 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sensitivity and specificity for the diagnosis of CLL (vs non-CLL) were calculated for the following markers: CD200, CD5, CD22, CD23, CD79b, FMC7, and SmIg.
|
29602219 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Together, these data confirm that CD23 protein is phosphorylated in B cells of B-CLL patients, report the identification of new CD23 phosphorylation sites, and suggest a possible role(s) of such phosphorylations in the activation of CD23 during the process of lymphocytic activation in B-CLL.
|
29763855 |
2018 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Together, these data confirm that CD23 protein is phosphorylated in B cells of B-CLL patients, report the identification of new CD23 phosphorylation sites, and suggest a possible role(s) of such phosphorylations in the activation of CD23 during the process of lymphocytic activation in B-CLL.
|
29763855 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD200 was of better diagnostic performance (accuracy: 94.6%) in differentiating CLL from MCL compared with CD23 (accuracy: 93.3%).
|
28752619 |
2018 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the genes identified, variants in T-box 21 ( TBX21) and Fc fragment of IgE receptor II ( FCER2) contribute indirectly to the variability in the response to ICS by altering the inflammatory mechanisms in asthma, while other genes such as corticotropin releasing hormone receptor 1 ( CRHR1), nuclear receptor subfamily 3 group C member 1 ( NR3C1), stress induced phosphoprotein 1 ( STIP1), dual specificity phosphatase 1 (DUSP1), glucocorticoid induced 1 (GLCCI1), histone deacetylase 1 (HDAC), ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3), and vascular endothelial growth factors (VEGF) directly affect this variability through the anti-inflammatory mechanisms of ICS.
|
29251255 |
2017 |